Rediscover your everyday

See how GIVLAARI may help reduce AHP attacks

GIVLAARI® (givosiran) is a prescription medicine
used to treat acute hepatic porphyria (AHP) in adults.

Amalia, patient with AIP

Individual results may vary

Video file
Video file

Rediscover your everyday

Amalia, patient with AIP

Individual results may vary

GIVLAARI® (givosiran) is a prescription medicine
used to treat acute hepatic porphyria (AHP) in adults.

See how GIVLAARI may help reduce AHP attacks

Amalia, an artist and patient on GIVLAARI, shares her AHP and treatment journey

Don't wait for the next attack.
Attack the disease.

Monthly appointment calendar

Once-monthly dosing

GIVLAARI is given once a month as a subcutaneous injection (under the skin) by a healthcare professional.

Green down arrow

Reduces levels of toxins

GIVLAARI reduces levels of aminolevulinic acid (ALA) and porphobilinogen (PBG), toxins associated with attacks and other AHP symptoms.

70% Fewer Attacks

Fewer porphyria attacks

In a 6-month study, on average, patients with AHP had their
attacks reduced by 70% after receiving GIVLAARI compared with those receiving placebo.

70% Hemin Use

Fewer days of hemin use

In a 6-month study, on average, patients with AHP had 70% fewer days of hemin use after receiving GIVLAARI compared with those receiving placebo.

Side effects icon

Most common side effects

In a 6-month study, the most common side effects of GIVLAARI were nausea and injection site reactions.

24 month

After the 6-month study, patients in the study experienced fewer attacks with continued treatment.

Attacks were defined as those that required hospitalization, urgent healthcare visit, or intravenous (IV) hemin administration at home.

Stay updated

Sign up for the latest news about GIVLAARI

All fields are required.

 
 

IMPORTANT SAFETY INFORMATION

Do not use GIVLAARI if you have ever had a severe allergic reaction to GIVLAARI.

  • Tell your doctor or nurse right away if you experience any of the following signs or symptoms of a severe allergic reaction during treatment:

    • Swelling – mainly of the lips, tongue or throat which makes it difficult to swallow or breathe
    • Breathing problems or wheezing
    • Feeling dizzy or fainting
    • Rash or hives
    • Itching

    If you have a severe allergic reaction, your doctor or nurse will stop GIVLAARI treatment right away and you may need to take other medicines to control the symptoms.

  • Your doctor will check your liver function by doing blood tests:

    • Before you start using GIVLAARI
    • Once a month for the first 6 months of treatment
    • And when they think it is needed

    If these tests show abnormal results, your doctor or nurse will decide whether to temporarily interrupt or stop treatment with GIVLAARI.

  • Your doctor will check how your kidneys are working while you are using GIVLAARI.

  • GIVLAARI is given as an injection under the skin (called a “subcutaneous injection”). Reactions to this injection may happen during treatment with GIVLAARI.

    Tell your doctor or nurse right away if you experience any of the following symptoms of an injection site reaction during treatment: redness, pain, itchiness, rash, discoloration, or swelling around the injection site.

  • GIVLAARI may cause increased levels of homocysteine (a type of amino acid) in your blood. Your doctor will check your homocysteine levels before and during treatment by doing blood tests. If your levels are increased, your doctor may check your folate, vitamins B12 and B6, and tell you to take a vitamin B6 supplement.

The most common side effects of GIVLAARI are nausea and injection site reactions. These are not all the possible side effects of GIVLAARI. Talk to your doctor about side effects that you experience. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-8 00-FDA -1088.


WHAT IS GIVLAARI® (givosiran)?

GIVLAARI is a prescription medicine used to treat acute hepatic porphyria (AHP) in adults.


For additional information about GIVLAARI, please see full Prescribing Information.